Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504).
South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579).
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501).
Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510).
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009).
Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients with prediabetes and/or obesity included in the phase I trial of inavolisib alone and in combination with endocrine therapy with or without palbociclib for PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (Abstract 1004).
